Evaluation of mouthwash, mouth spray, and nasal spray as treatment of COVID-19 patients and prevention of individuals at risk of exposure to COVID-19 infection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240803002

Enrollment

100

Registered

2024-08-03

Start date

2022-05-18

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 mouthwash, mouth spray, nasal spray, COVID-19 infection

Interventions

COVID-19 patients and high-risk group volunteers used the product (mouthwash, mouth spray, and nasal spray) continuously for 7 days. Mouthwash: Use 10 ml (or 1 screw cap). First, swish in the mouth f

Experimental Other,Placebo Comparator Other

Limonene,Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Be 18 years of age or older on the date of submitting the consent form. 2. Women must not be pregnant or breastfeeding. 3. If you are a married woman of reproductive age, you must use birth control for at least 1 month before entering the trial. Acceptable birth control methods include taking birth control pills, injections, birth control rings, birth control implants, or using condoms. This must continue until the experiment is completed. 4. Do not drink alcohol or smoke. 5. You must not be in the process of losing weight and must have no history of allergies to drugs, cosmetics, chemicals, or natural extracts. 6. Volunteers will receive training on product use and detailed information about the consent documentation.

Exclusion criteria

Exclusion criteria: 1. Project participants have a serious illness (acute illnesses) or require hospitalization within 3 days of joining the project. 2. Participants have used other nasal sprays, especially steroids, in the past 7 days. 3. Project participants have previously undergone a tracheotomy (tracheostomy). 4. Project participants are receiving oxygen therapy. 5. Females who are breastfeeding, pregnant, or intending to become pregnant. 7. People with mental or nervous system disabilities that prevent independent use of the product.

Design outcomes

Primary

Measure	Time frame
cough 7 days 5-point Likert scale,sore throat 7 days 5-point Likert scale,runny nose 7 days 5-point Likert scale	—

Secondary

Measure	Time frame
Satisfaction 7 days 5-point Likert scale	—

Countries

Thailand

Contacts

Public ContactChutima Limmatvapirat

Faculty of Pharmacy, Silpakorn University

limmatvapirat_c@su.ac.th0634462703

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026